Ipsen Announces That Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival in Patients with Advanced Hepatocellular Carcinoma
Go back to Ipsen Announces That Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival in Patients with Advanced Hepatocellular Carcinoma| Exelixis, Inc. (NASDAQ: EXEL) | Delayed: 57.22 -1.14 (1.95%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $58.36 | 52 Week High | $17.00 | |||
| Open | $58.61 | 52 Week Low | $3.55 | |||
| Day High | $58.81 | P/E | N/A | |||
| Day Low | $56.90 | EPS | $-1.33 | |||
| Volume | 2,091,101 | |||||
| SPDR S&P INTERNATIONAL INDUSTRIAL SECTOR (NYSE: IPN) | Delayed: 34.71 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $34.71 | 52 Week High | $30.88 | |||
| Open | $0.00 | 52 Week Low | $24.64 | |||
| Day High | $34.71 | P/E | N/A | |||
| Day Low | $34.71 | EPS | $0.00 | |||
| Volume | 741,680 | |||||
| Ipsen S.A. Sponsored ADR (AMEX: IPSEY) | Delayed: 42.41 -2.34 (5.23%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $44.75 | 52 Week High | $17.79 | |||
| Open | $42.41 | 52 Week Low | $13.01 | |||
| Day High | $42.41 | P/E | N/A | |||
| Day Low | $42.41 | EPS | $0.00 | |||
| Volume | 241 | |||||
